Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data
Open Access
- 1 November 1994
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 70 (5) , 908-913
- https://doi.org/10.1038/bjc.1994.419
Abstract
Ewing tumours (ET), including Ewing's sarcoma and peripheral primitive neuroectodermal tumour, are well characterised at the molecular level by a unique chromosomal rearrangement which fuses the EWS gene to one of two closely related ETS proto-oncogenes, FLI-1 or ERG. Expression of the resulting chimaeric transcripts can be readily detected by reversed transcriptase polymerase chain reaction (RT-PCR). This approach led to the identification of a number of different exon combinations at the junction site of coding sequences. The physiological consequences of the observed variability in the hinge region of EWS chimaeric proteins are not known. We have analysed tumour-derived material from 30 ET patients with well-documented clinical course (18 with localised and 12 with metastatic disease at diagnosis) for the presence of EWS/FLI-1 or EWS/ERG RNA. Karyotypes were obtained in 21 out of 27 cases and analysed by routine cytogenetics. A chromosome 22 rearrangement was demonstrated in 18 cases (67%). In contrast, RT-PCR revealed the presence of chimaeric transcripts in 28 tumours (93%), with fusions of EWS exon 7 to FLI-1 exons 6 (19/28), 5 (4/28) and 7 (1/28). In addition, EWS/FLI-1 exon combinations 10/5 and 9/4 were observed in one case each. In the last tumour, the presence of at least four additional splicing variants corresponding to fusion of EWS exon 7 to FLI-1 exons 4, 6, 8 and 9 was demonstrated. Two tumours expressed EWS/ERG fusion transcripts involving EWS exon 7 and ERG exon 6. In this study, EWS/FLI-1 exon combinations 7/6 (type I) predominated over 7/5 (type II) in localised ET (14 versus 1) and were more abundant in tumours affecting the long bones (9 versus 0), whereas in central axis tumours and metastatic disease there was only little difference in the frequency of the two types. So far, no correlations between different chimaeric EWS transcripts and any other clinical parameters have been identified.Keywords
This publication has 18 references indexed in Scilit:
- A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERGNature Genetics, 1994
- Unexpected heterogeneity in E2A/PBX1 fusion messenger RNA detected by the polymerase chain reaction in pediatric patients with acute lymphoblastic leukemia.1992
- Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumoursNature, 1992
- MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberrationCancer, 1991
- Mononuclear cell (MNC) concentration from the marrow harvest by automatic system.1991
- High-Dose Melphalan, Etoposide ± Carboplatin (Mec) Combined with 12-Gray Fractionated Total-Body Irradiation in Children with Generalized Solid TumorsPediatric Hematology and Oncology, 1991
- OVEREXPRESSION OF THE PSEUDOAUTOSOMAL GENE MIC2 IN EWINGS-SARCOMA AND PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR1990
- Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases and remarkable consistency of t(11;22)(q24;q12)Cancer Genetics and Cytogenetics, 1988
- Multidisciplinary treatment of primary Ewing's sarcoma of bone.A 6-year experience of a European cooperative trialCancer, 1988
- Chromosome Translocation in Peripheral NeuroepitheliomaNew England Journal of Medicine, 1984